Drs. Su and O'Sullivan’s lab identifies UTX as the key driver of sex differences in NK cell Antiviral Activity
A collaborative study between the labs of Dr. Maureen Su and Dr. Tim O'Sullivan identified the X-linked epigenetic regulator UTX as a key driver of sex differences in NK cell antiviral activity. These findings mirror the clinical observation that males tend to have worse outcomes after viral infection despite having more peripheral NK cells, leading to important implications for personalized medicine and cell therapy.
Dr. O'Sullivan suggested that in the future, immunotherapy treatments may be derived from women.
This study was published in Nature Immunology and featured on the cover of the May 2023 issue as well as a feature on Salon.
Related Articles
Dr. Donald B. Kohn receives the American Society of Gene + Cell Therapy Founders Award
Congratulations on this achievement, Dr. Kohn!
Glutamine Sensing licenses Cholesterol Synthesis
This study demonstrates that glutamine is directly sensed by and required for activation of the mevalonate pathway.
Immune-based Treatment gets a Boost to its Cancer-Fighting Superpowers
UCLA-developed platform mimics nature to enhance T cell-based therapies in collaborative study between Dr. Lili Yang and UCLA Researchers.